Discover an informative webinar delving into DNA-encoded library (DEL) technology in drug discovery, showcasing tailored campaigns, parallel screening and innovative hit identification for challenging targets. DEL technology is a powerful methodology for small molecule drug discovery. In this webinar, the featured speakers will share X-Chem’s DEL screening experience, with an emphasis on tailoring DEL campaigns to specific targets and project goals.
In contrast to traditional high-throughput screening, a DEL screening campaign consists of multiple parallel screening conditions, allowing more shots on goal as well as deep profiling of the enriched hits’ selectivity and binding mode. This webinar will highlight several successful examples that benefited from the judicious design of parallel screening conditions.
For challenging targets, it is often necessary to rigorously characterize target protein activity and optimize screening buffers, which has proved crucial for effective hit identification. Moreover, there are new screening methods for discovering compounds with novel mechanisms of action, including covalent inhibitors and molecular glues. These examples illustrate how innovative thinking and a sophisticated approach to DEL screening campaign design can bring success to challenging drug discovery projects.
Register for this webinar to discover tailored DEL campaigns and innovative hit identification for challenging targets.
Dr. Zhen Chen, PhD, Senior Principal Research Scientist, X-Chem
Dr. Zhen Chen is a Senior Principal Research Scientist at X-Chem, Inc., using DNA-encoded library (DEL) technology to rapidly discover high-quality lead compounds for challenging targets. He also spearheads multiple technology development efforts to further expand the capabilities of DEL and streamline the data analysis process. Prior to X-Chem, he earned his PhD in Chemistry and Chemical Biology in David Liu’s lab at Harvard University, where he evolved nucleic acid polymers functionalized with protein-like side chains to bind protein targets of therapeutic interest.
Anthony Keefe, PhD, Senior Vice President, Alliance Management and Innovation, X-Chem
Dr. Anthony (Tony) Keefe has over 20 years of experience with the use of encoded libraries and affinity-mediated discovery methods. He joined X-Chem in 2010 as senior director of lead discovery. From 2001 to 2009, he worked at Archemix Corp., where he developed the first-ever fully modified aptamers, thus improving the therapeutic potential of such candidate antagonists by making them highly resistant to biologically mediated degradation. From 1997 to 2001, he was a postdoctoral fellow in the laboratory of Nobel Laureate Jack Szostak at Harvard Medical School/Massachusetts General Hospital, developing mRNA display technology.
Tony’s achievements in the Szostak lab include the discovery of the first novel functional protein fold to have been discovered independent of biology and the introduction of a novel protein affinity tag. He is an Author of over 50 publications and is listed as an inventor on 13 granted US patents and 30 patent applications. He is also a member of the editorial board of the journal Nucleic Acid Therapeutics. Tony received his BSc in Chemistry from Exeter University in UK, in 1985, and his PhD in Chemistry from the University of Birmingham in UK, in 1989.
Who Should Attend?
This webinar will appeal to professionals in the following fields:
- Current DEL practitioners
- Teams with challenging targets interested in hit identification using DEL screens
What You Will Learn
Attendees will gain insights into:
- The value of multiple parallel screening conditions
- Quality control and unusual buffer components
- New screening methods
X-Chem is a leader in small molecule drug discovery services for pharmaceutical and biotech companies. As pioneers of DNA-encoded chemical library (DEL) technology, the company leverages its market-leading DEL platform to discover novel small molecule leads against challenging, high-value therapeutic targets. As experts in medicinal chemistry, X-Chem can take those leads and progress them to clinical candidates with unmatched speed. Throughout the process, X-Chem’s advanced proprietary artificial intelligence (AI) technology accelerates all steps in the process. X-Chem also provides libraries, reagents and informatic tools to allow DEL operators to get the most of their DEL platform. X-Chem empowers its partners to effectively build drug pipelines from target to clinical candidate, enhanced with AI. For further information, please visit www.x-chemrx.com.